27 January 2025 in Drug and Alcohol Dependence
Drug checking is a harm reduction strategy that provides people who use drugs (PWUD) information about the composition of a substance. Drug checking has been identified as a key public health response to the continually evolving overdose crisis. The New York City Health Department of Health and Mental Hygiene (DOHMH) partnered with existing syringe programs to launch a drug-checking pilot study. The study offered multiple point-of-care drug-checking technologies including fentanyl test strips (FTS) and Fourier-transformed infrared (FTIR) spectrometry, as well as secondary laboratory testing. Fentanyl positivity in major drug types was assessed for each drug-checking technology. Between November 2021 and December 2023, a total of N = 397 unique participants and drop-off samples contributed a total of N = 1644 samples for drug checking. The majority of samples were sold as opioids (n = 908), with fewer sold as cocaine (n = 314) and methamphetamine (n = 62). 95.3 % (852/894) of opioid samples produced positive FTS. FTIR and secondary laboratory testing resulted in a similarly high prevalence of fentanyl in opioid samples at 84.7 % (769/908) and 89.3 % (519/581), respectively. We did not observe the unexplained presence of fentanyl in samples sold as cocaine or methamphetamine. Further, we describe instances where discussions between technicians and PWUD provided important context that explained the presence of fentanyl in non-opioid samples. The majority of opioid samples submitted to DOHMH's drug-checking pilot study contained fentanyl. Comparatively, there was little evidence suggesting fentanyl in samples sold as cocaine and methamphetamine. The drug-checking pilot study's point-of-care service delivery model was effective in providing information to PWUD.
19 November 2025 in Substance use & addiction journal
LGLeonardo Dominguez Gomez
+2
Background: Drug checking is an evidence-based harm reduction strategy that can contribute to safer use by providing people who use drugs (PWUD) with actionable information about the contents of the drugs they are using and ways to reduce harm. In response to persistently high overdose rates largely driven by adulteration and volatility of the unregulated drug supply, the New York City Department of Health & Mental Hygiene (NYC DOHMH) initiated a point-of-care drug-checking pilot study in partnership with syringe service programs. Methods: Drug-checking services were piloted at 6 sites over the study period. DOHMH staff were trained to use immunoassay test strips and Fourier-transform Infrared Spectrometers, analyze and interpret drug-checking results, and provide tailored harm reduction education to participants. Samples were sent for secondary testing to support technician training and quality assurance. Participant demographics, information about the drug sample, and how individuals planned to use the results were collected and entered into a REDCap database. Results: From November 2021 through December 2023, more than 1600 samples were submitted for analysis. Over half of the samples were sold as opioids (55%; n = 903). The presence of fentanyl in samples sold as opioids was very high (95%; n = 859). Xylazine was detected in 35.0% (n = 201) of opioid samples for which secondary laboratory results were available. 51.5% of participants indicated that they planned to employ a harm reduction strategy or take some other action following receipt of their drug-checking results. Conclusion: Findings from the pilot study demonstrate that it is feasible and acceptable for local health departments to implement point-of-care drug-checking services in partnership with programs that serve PWUD. For some participants, drug-checking interactions may support behavioral intention changes about the drugs they use. Key implementation considerations include the importance of a robust technician training model, selection of appropriate and complementary drug-checking technologies, and availability of secondary lab testing.
6 September 2026 in Drug and Alcohol Review
Introduction: Drug checking is a harm reduction strategy that provides information to people who use drugs. Currently, there is a lack of standardised, replicable methods to assess drug checking technicians' use of spectroscopy‐based technologies. Methods: This paper introduces concordance analysis as a method to assess drug checking technician accuracy using Fourier transform infrared (FTIR) spectroscopy. Drug checking technicians provided point‐of‐care drug checking services, including FTIR, at participating syringe service programs in New York City beginning in November 2021. Drug checking technicians analysed drug samples and identified compounds based on spectra, test strips and contextual information provided by the individuals submitting samples. The drug checking technician results were compared to results obtained from a secondary laboratory testing partner. Technicians aimed to achieve a 90% concordance rate for sample composition determinations in the field as compared to secondary laboratory testing results. Results: Two drug checking technicians encountered a total of N = 362 samples over the course of their training periods. Concordance analysis showed that both technicians completed their training period above the target accuracy level (Technician A 137/151 or 90.7% concordant, Technician B 196/211 or 92.9% concordant). The training periods for Technician A and Technician B were 33 and 38 weeks, respectively. Both technicians demonstrated improvement over time. Discussion and Conclusions: These results indicate that drug checking technicians with no formal background in analytical chemistry are able to accurately identify compounds present in real‐world drug samples using an FTIR, thus supporting the merit of these techniques in drug checking programs.
12 March 2026 in International Journal of Drug Policy
LGLeonardo Dominguez Gomez
+1
Drug checking is an increasingly common harm reduction service available across the United States. However, evidence of whether drug-checking data is associated with population-level health measures is limited. Beginning in November 2021, the New York City (NYC) Health Department partnered with syringe service programs (SSP) to initiate a drug checking pilot study. SSP participants submitted drug samples for point-of-care drug checking and secondary lab testing. Time series generalized additive modeling (GAM) techniques were used to examine whether there was an association between the prevalence of specific compounds and drug-involved overdose death rates. Separate models were fit to evaluate: (1) xylazine prevalence and the xylazine-involved overdose death rate and (2) fentanyl prevalence and the overall drug-involved overdose death rate. Models were adjusted for calendar month RESULTS: A total of N = 26 months of study data were analyzed (November 2021 through December 2023), during which N = 5549 drug involved overdose deaths occurred and N = 594 drug checking samples contained an opioid. A significant nonlinear association was observed between the prevalence of xylazine in drug checking samples and the rate of overdose deaths involving xylazine. In addition, a significant nonlinear association was observed between fentanyl prevalence in drug checking samples and the overall rate of overdose deaths. These findings provide evidence that point-of-care drug checking can produce data that correlate with the drug-involved overdose death rate. This predictive capacity, as well as the timeliness of point-of-care drug checking data, lend support for the role of drug checking as both a harm reduction service and public health monitoring tool.